LOS ANGELES, Nov. 15, 2023 (GLOBE NEWSWIRE) — BlackLine, Inc. (Nasdaq: BL) today announced that BlackLine’s management team will participate in the following upcoming investor conference:
UBS Global Technology Conference
Wednesday, November 29th, 2023
Presentation time: 1:35 pm MT
Location: Scottsdale, AZ
The webcast and replay will be available on BlackLine’s investor relations website at https://investors.blackline.com.
Companies come to BlackLine (Nasdaq: BL) because their traditional manual accounting and finance processes are not sustainable. BlackLine’s market-leading cloud platform and customer service help companies move to modern accounting by unifying their data and processes, automating repetitive work, and driving accountability through visibility. BlackLine provides solutions to manage and automate financial close and consolidation, accounts receivable, and intercompany accounting processes – inspiring, powering, and guiding large enterprises and midsize businesses on their digital finance transformation journeys.
More than 4,300 customers trust BlackLine to help them close faster with complete and accurate results. The company is the pioneer of the cloud financial close market and is recognized as the leader by customers at leading end-user review sites including G2 and TrustRadius. BlackLine is a global company with operations in major business centers including Los Angeles, New York, the San Francisco Bay area, London, Paris, Frankfurt, Tokyo, Singapore, and Sydney.
For more information, please visit blackline.com.
Investor Relations Contact:
Matt Humphries, CFA
- FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting - December 9, 2023
- FTCH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Farfetch Limited Investors with Substantial Losses Have Opportunity to Lead Case - December 9, 2023
- Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - December 9, 2023